PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING

May 1, 2008, 00:00
10.1016/S1098-3015(10)70622-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)70622-7/fulltext
Title : PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70622-7&doi=10.1016/S1098-3015(10)70622-7
First page :
Section Title :
Open access? : No
Section Order : 353
Categories :
Tags :
Regions :
ViH Article Tags :